



IFW

PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/824,097	
Filing Date	April 13, 1004	
First Named Inventor	Steve J.D. Bell	
Art Unit	1615	
Examiner Name	Not Assigned	
Total Number of Pages in This Submission	Attorney Docket Number	37070/293555

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 127 Non-US publications 9 sheets of PTO-1449
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Catherine E. Fienning, Reg. No. 54,095 Kilpatrick Stockton LLP
Signature	
Date	October , 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. **Mail Stop Amendment**

Typed or printed name	Colleen Kadian		
Signature		Date	October 19, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Steve J.D. Bell)
)
Serial No. 10/824,097) Examiner: Not Assigned
)
Filing Date: April 13, 2004) Art Unit: Not Assigned
)
For: Methods Of Manufacture And Use Of) Docket No.: 37070/293555
Calcium Phosphate Particles Containing Allergens)

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this document and all documents referred thereon as enclosed is being transmitted to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313 on: October 19, 2004


Colleen Kadian

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the Form-1449 are enclosed for consideration by the Examiner

Submission of the references provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

This Information Disclosure Statement is being filed pursuant to 37 C.F.R. 1.97(b), before issuance of a first Office action on the merits. Applicants believe that no fee is due for


INFORMATION DISCLOSURE STATEMENT

U.S. Patent Application No.: 10/824,097

Title: Methods of Manufacture And Use Of Calcium Phosphate Particles Containing Allergens


submission and consideration of this paper. The Commissioner is authorized to charge any fees associated with this filing or credit any overpayment to Deposit Account No. 11-0855.

Respectfully submitted,



Catherine E. Fienning, Reg. No. 54,095
Attorney for Assignee

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309
Direct Phone: 404-532-6959
General Phone: 404-815-6500



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket No.: 37070/293555		Application No. 10/824,097			
		Applicant: Steve J. D. Bell					
		Filing Date: April 13, 2004		Group Art Unit 1654			
U. S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Patentee		Subclass	Translation
		3,183,545	06/29/61	Bergstrom			
		3,382,150	05/07/68	Grass, et al.			
		3,925,545	12/09/75	Relyveld			
		3,983,229	09/28/76	Relyveld			
		4,016,252	04/05/97	Relyveld			
		4,070,454	01/24/78	Relyveld			
		4,075,321	02/21/78	Relyveld			
		4,350,686	09/21/82	Relyveld, et al.			
		4,500,512	02/19/85	Barme			
		4,552,756	11/12/85	Relyveld, et al.			
		4,625,019	11/25/86	Relyveld			
		4,929,774	05/29/90	Fukamachi, et al.			
		4,963,526	10/16/90	Ecanow			
		5,110,606	05/05/92	Geyer, et. al			
		5,178,882	01/12/93	Kossovsky et al.			
		5,219,577	06/15/93	Kossovsky et al.			
		5,306,508	04/26/94	Kossovsky et al.			
		5,318,913	06/07/94	Relyveld			
		5,334,394	08/02/94	Kossovsky et al.			
		5,364,838	11/15/94	Rubsamen			
		5,428,066	06/27/95	Larner, et al.			
		5,460,830	10/24/95	Kossovsky et al.			
		5,460,831	10/24/95	Kossovsky et al.			
		5,462,750	10/31/95	Kossovsky et al.			
		5,462,751	10/31/95	Kossovsky et al.			
		5,464,634	11/07/95	Kossovsky et al.			
		5,469,599	11/28/95	Wurdack			
		5,506,203	04/09/96	Backstrom et al.			
		5,549,973	08/27/96	Majetich et al.			
		5,580,859	12/03/96	Felgner et al.			
		5,593,875	01/14/97	Wurm, et al.			
		5,595,762	1/21/97	Derrieu et al.			
		5,618,800	04/08/97	Kabra, et al.			
		5,620,896	04/15/97	Herrmann et al.			
		5,629,021	05/13/97	Wright			
		5,641,515	06/24/97	Ramtoola			
		5,648,097	7/15/97	Nuwayser			
		5,665,382	09/09/97	Grinstaff, et al.			
		5,695,617	12/09/97	Gravier et al.			
Examiner:				Date Considered:			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket No.: 37070/293555	Application No. 10/824,097
	Applicant: Bell et al.	
	Filing Date: April 13, 2004	Group Art Unit 1654
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Al-Achi, et al., "Erythrocytes as Oral Delivery Systems for Human Insulin," <i>Drug Development and Industrial Pharmacy</i> , 24(1):67-72 (1998)	
	Aldovini and R. A. Young, "Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines," <i>Nature</i> 351: 479-482 (1991).	
	Alward, "Medical Management of Glaucoma, <i>N. Eng. J. Med.</i> , 339:1298-1307 (1998)	
	Ascadi et al., "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," <i>Nature</i> 352: 815-818 (1991).	
	Bartus et al., "Sustained Delivery of Proteins for Novel Therapeutic Products," <i>Science</i> , 281(5380): 1161-1162 (1998).	
	Bastin, et al., "Use of Synthetic Peptides of Influenza Nucleoprotein to Define Epitopes Recognized by Class I-Restricted Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> , 165(4): 1508-1523 (1987).	
	Bayomi, M.A., "Preparation of casein-chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique," <i>Pharma. Acta. Helv.</i> , 73(4):187-92 (1998). (abstract)	
	Benvenisty, N., and Reshef, L. "Direct introduction of genes into rats and expression of genes," <i>PNAS</i> 83, 9551-9555, (1986)	
	Bennink and J. W. Yewdell, "Recombinant Vaccinia Viruses as Vectors for Studying T Lymphocyte Specificity and Function," <i>Curr. Top. Microbiol. Immunol.</i> , 163: 153-184 (1990)	
	Bochot, et al., "Intravitreal delivery of oligonucleotides by sterically stabilized liposomes," <i>Invest. Ophthalmol. Vis. Sci.</i> , 43(1):253-259 (2002)	
	Bousquet, et al., "Allergen immunotherapy : therapeutic vaccines for allergic diseases," <i>Annals of Allergy, Asthma & Immunology</i> , 81:401-405 (1998)	
	Bousquet, "Allergy Tests and Therapy," <i>Allergy Tests and Therapy, The Buyer's Guide to Respiratory Care Products</i> , pp. 8-10 (undated)	
	Brubaker, "Measurement of aqueous flow by fluorophometry," In <i>Glaucoma</i> , Ritch, et al., Editors, Mosby, St. Louis, pp. 337-344 (1989)	
	Brubaker, "Mechanism of Action of Bimatoprost (Lumigan TM), <i>Survey of Ophthalmology</i> , 45(4):S347-S351 (2001)	
	Bulgarelli, et al., "Effect of matrix composition and process conditions on casein-gelatin beads floating properties," <i>Int. J. Pharm.</i> , 198(2):157-65 (2000). (abstract)	
	Bulgarelli, et al., "Casein/gelatin beads: I. Cross-linker solution composition effect on cross-linking degree," <i>Int. J. Pharm.</i> , 190(2):175-182 (1999). (abstract)	
	Carbone and Bevan, "Induction of Ovalbumin-specific cytotoxic T cells by in vivo peptide immunization," <i>J. Exp. Med.</i> , 169(1): 603-612 (1989).	
	Chen, et al., Comparison of albumin and casein microspheres as a carrier for doxorubicin, <i>J. PHARM. PHARMACOL.</i> , 39(12):978-85 (1987)	
	Choudhari, et al., Liposomes As a Carrier for Oral Administration of Insulin: Effect of Formulation Factors, 11 (3) <i>JOURNAL OF MICROENCAPSULATION</i> , 319-325 (1994)	
Examiner:	Date Considered:	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket No.: 37070/293555	Application No. 10/824,097
	Applicant: Bell et al.	
	Filing Date: April 13, 2004	Group Art Unit 1654
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Chu, et al., "Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: A dopamine ₃ receptor agonist," <i>J. of Pharmacology and Experimental Therapeutics</i> , 293(3):710-716 (2000)	
	Chu, et al., "Potential sites of action of TNPA: A dopamine-2 receptor agonist," <i>Exp. Eye Res.</i> , 69:611-616 (1999)	
	Chu, et al., "Biodegradable Calcium Phosphate Nanoparticles as a New Vehicle for Delivery of a Potential Ocular Hypotensive Agent," <i>J. of Ocular Pharmacology and Therapeutics</i> , 18(6):507-514 (2002)	
	Collins et al., "Processing of exogenous liposome-encapsulated antigens in vivo generates class I MCH-restricted T cell responses," <i>J. Immunol.</i> , 148(11): 3336-3341 (1992).	
	Cooney et al., "Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein," <i>Lancet</i> , 337: 567-572 (1991).	
	Cox et al., "Bovine Herpesvirus 1: Immune Responses in Mice and Cattle Injected with Plasmid DNA," 1993, <i>J. Virol.</i> , 67(9): 5664-5667.	
	Damge, et al., "New approach for Oral Administration Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier," <i>Diabetes</i> , 37:246-251 (1988)	
	Damge, et al., "Poly(alkyl cyanoacrylate) Nanospheres for Oral Administration of Insulin," <i>J. Pharm. Sci.</i> , 86(12):1403-1409 (1997)	
	De Campos, et al., "Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A," <i>Int. J. Pharm.</i> , 224:159-168 (2001)	
	Deres, et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipoprotein vaccine," <i>Nature</i> , 342: 561-564 (1989).	
	Donnelly et al., "DNA Vaccines," <i>Annu. Rev. Immunol.</i> , 15: 617-648 (1997).	
	Edgington, "Turning On Tumor-Fighting T-Cells," <i>Biotechnology</i> , 11:1117-1119 (1993).	
	Edwards et al., "Large Porous Particles for Pulmonary Drug Delivery," <i>Science</i> , 276:1868-1871 (1997).	
	Friedman, T., "Progress toward human gene therapy," <i>Science</i> , 244, 1275-1281 (1989).	
	Furth et al., "Gene Transfer into Somatic Tissues by Jet Injection," <i>Analytical Biochemistry</i> , 205(2): 365-368, (1992).	
	Gardner et al., "Cell-mediated cytotoxicity against ectromelia virus-infected target cells," <i>Eur. J. Immunol.</i> , 4: 68-72 (1974).	
	Goto, et al., Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines, <i>Vaccine</i> , 11 :914-918 (1993)	
	Goto, et al., "Toxicity of Aluminum Compounds as an Adjuvant for Vaccines," <i>Aluminum Toxicity in Infants' Health and Disease</i> , Chapter 15, pp. 208-224 (1997)	
	Goto et al., "Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminum hydroxide with different physical properties," <i>Vaccine</i> , 15(12/13):1364-1371 (1997)	
	Gupta, et al., "Adjuvant Properties of Aluminum and Calcium Compounds," <i>Vaccine Design: The Subunit and Adjuvant Approach</i> (1995)	
Examiner:		Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket No.: 37070/293555	Application No. 10/824,097
	Applicant: Bell et al.	
	Filing Date: April 13, 2004	Group Art Unit 1654
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Hahn et al., "Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation," <i>Proc. Natl. Acad. Sci. (USA)</i> 89: 2679-2683 (1992).	
	Hansen et al., "Strong Expression of Foreign Genes Following Direct Injection into Fish Muscle," <i>FEBS Lett.</i> 290, 73-76 (1991).	
	He, et al., "Calcium Phosphate Nanoparticle Adjuvant," <i>Clin. Diag. Laab. Immuno.</i> 7(6):899-903 (2000)	
	He, et al., "Calcium Phosphate Nanoparticles Induce Mucosal Immunity and Protection Against Herpes Simplex Virus Type 2," <i>Clinical and Diagnostic Laboratory Immunology</i> , pp. 1021-1024 (September 2002)	
	Heelan, et al., "In vitro analysis of the release of incorporated agents from sodium caseinate microspheres," <i>J. Microencapsul.</i> , 14(1):63-78 (1997). (abstract)	
	Hosny, et al., "Promotion of oral insulin adsorption in diabetic rabbits using pH-dependent coated capsules containing sodium cholate," <i>Pharm. Acta. Helv.</i> , 72(4):203-7 (1997). (abstract)	
	Hosny, "Hypoglycemic Effect Of Oral Insulin in Diabetic Rabbits Using pH-Dependent Coated Capsules Containing Sodium Salicylate Without And With Sodium Cholate," 24(3) <i>DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY</i> 24(3):307-311 (1998)	
	Hoyng, et al., "Pharmacogical therapy for glaucoma, <i>Drugs</i> , 59(3):411-434 (2000)	
	Ickovic, et al, "Calcium-Phosphate-Adjuvanted Allergens: Total and Specific IgE Levels Before And After Immunotherapy With House Dust And Dermatophagoides Pteronyssinus Extracts," <i>Ann. Immunol. (Inst. Pasteur)</i> 134 D, 385-398 (1983)	
	Jiao, et al., <i>Hum. Gene Therapy</i> , 3:21 (1992).	
	Kato et al., "Relationship between Hemolytic Activity and Adsorption Capacity of Aluminum Hydroxide and Calcium Phosphate as Immunological Adjuvants for Biologicals," <i>Microbiol. Immunol.</i> , 38(7): 543-548 (1994).	
	Kimura, et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, 19(6) <i>BIOL. PHARM. BULLETIN</i> , 19(6):897-900 (1996). (abstract)	
	Kitsis et al., "Hormonal modulation of a gene injected into rat heart <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. (USA)</i> 88: 4138-4142 (1991).	
	Knepp, "Synthesis, properties, and intratumoral evaluation of mitoxantrone-loaded casein microspheres in Lewis lung cacimnoma," 45(10) <i>J. PHARM. PHARMACOL</i> , 887-91 (1993). (abstract)	
	Lamprecht, et al., "Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease," <i>J. Pharm. Exper. Thera.</i> 299(2):775-781 (2001)	
Examiner:		Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket No.: 37070/293555	Application No. 10/824,097
		Applicant: Bell et al.	
		Filing Date: April 13, 2004	Group Art Unit 1654
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Latha, "Progesterone release from glutaraldehyde cross-linked casein microspheres: in vitro studies and in vivo response in rabbits," 61(5) <i>CONTRACEPTION</i> , 329-34 (2000). (abstract)	
		Latha, "Glutaraldehyde cross-linked bovine casein microspheres as a matrix for the controlled release of theophylline: in-vitro studies," 46(1) <i>J. PHARM. PHARMACOL</i> , 8-13 (1994). (abstract)	
		Latha, et al., "Casein as a carrier matrix for 5- fluorouracil: drug release from microspheres, drug-protein conjugates and in-vivo degradation microspheres in rat muscle," 46(11) <i>J. PHARM. PHARMACOL</i> , 858-62 (1994)	
		Latha, et al., "A new method for the synthesis of smooth, round, hydrophilic protein microspheres using low concentrations of polymeric dispersing agents," <i>J. Microencapsl.</i> , 12(1):7-12 (1995). (abstract)	
		Lery, "Haemolytic activity of calcium phosphate adjuvant," <i>Vaccine</i> , 12(5):475	
		Li, et al., "Ocular drug delivery of progesterone using nanoparticles," <i>J. Microencapsul.</i> , 3(3):213-218 (1986)	
		Lin et al., "Expression of Recombinant Genes in Myocardium In Vivo after Direct Injection of DNA," <i>Circulation</i> 82(6): 2217-2221 (1990).	
		Lin and Askonas, "Biological properties of an influenza A virus-specific killer T cell clone," <i>J. Exp. Med.</i> 154(1): 225-234 (1981).	
		Lowman, "Oral Delivery of Insulin Using pH-Responsive Complexation Gels," 88(9) <i>JOURNAL OF PHARMACEUTICAL SCIENCES</i> , 933-937 (1999)	
		Maniatis, et al., " <i>Molecular Cloning</i> , A laboratory Manuel, 2 nd Edition," Cold Spring Harbor Laboratory Press, New York, 1.0 – 19.0 (1989).	
		Mascola et al., "Surveillance of Listeriosis in Los Angeles County, 1985-1986," <i>Arch. Intern. Med.</i> , 149(7): 1569-1572 (1989).	
		McMichael et al., "Cytotoxic T-Cell Immunity to Influenza," <i>New Engl. J. Med.</i> , 309(1): 13-17 (1983).	
		McMichael et al., "Recognition of Influenza A virus Nucleoprotein by human cytotoxic T lymphocytes," <i>J. Gen. Virol.</i> , 67: 719-726 (1986).	
		Michel, et al., "The Effect of Site of Administration in the Gastrointestinal Tract on the Absorption of Insulin from Nanocapsules in Diabetic Rats," <i>J. Pharm. Pharmacol.</i> , 43:1-5 (1991)	
		Miller, "Retroviral Vectors," <i>Curr. Top. Microbiol. Immunol.</i> , 158, 3-24 (1992).	
		Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors, <i>DNA and Cell. Biol.</i> , 12:777-783 (1993)	
		Musabayane, et al., Orally administered, insulin-loaded amidated pectin hydrogel beads sustain plasma concentrations of insulin in streptozotocin-diabetic rats, 164(1) <i>JOURNAL OF ENDOCRINOLOGY</i> , 1-6 (2000)	
		Naylor, et al., "Comparison of the mechanism of dissolution of hydrocortisone in simple and mixed micelle systems," <i>Pharm. Res.</i> 10(6):865-70 (1993). (abstract)	
		Neefjes, et al., "Cell Biology of Antigen Presentation," <i>Curr. Opin. Immunol.</i> , 5(1):27-34 (1993)	
Examiner:		Date Considered:	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket No.:	37070/293555	Application No.
	Applicant:	Bell et al.	
	Filing Date:	April 13, 2004	Group Art Unit 1654
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		O'Hehir, "Immunology and allergy," <i>The Medical Journal of Australia</i> , 176(1):22 (2002)	
		Ogidigben, et al., "Comparative effects of alpha-2 and DA-2 agonists on intraocular pressure in pigmented and nonpigmented rabbits, <i>J. of Ocular Pharmacology</i> , 9(3):187-199 (1993)	
		Ogidigben, et al., "Ocular hypotensive action of a dopaminergic (DA ₂) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine, <i>J. Pharmacol. Exp. Ther.</i> , 267:822-827 (1993)	
		Olivares, et al., Effects of a Protective Hydrolyzed Casein Diet Upon the Metabolic and Secretory Responses of Pancreatic Islets to IL-1 β , Cytokine Production by Mesenteric Lymph Node Cells, Mitogenic and Biosynthetic Activities and Peyer's Patch Cells, and Mitogenic Activity and Pancreatic Lymph Node Cells from Control and Diabetes-Prone BB Rats, 68(3) <i>MOLECULAR GENETICS AND METABOLISM</i> 379-390 (1999)	
		Potter, "Do dopamine and dopamine receptors have roles in modulating function in the anterior segment? The evidence. <i>In Progress in Retinal and Eye Research</i> , Osborne, N.N. and Chader, G.J, Editors, Elsevier Sciences Ltd., New York, pp 103-111 (1995)	
		Powell, et al., "Adjuvant Properties of Aluminum and Calcium Compounds," <i>Vaccine Design</i> , 229-248 (1995)	
		Redfield et al., "Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease," <i>New Engl. J. Med.</i> , 316(11): 673-676 (1987).	
		Relyveld, et al. "Calcium Phosphate Adjuvanted Allergens," <i>Annals of Allergy</i> , 54:521-528 (1985)	
		Relyveld, et al., "Preparation and Use of Calcium Phosphate Adsorbed Vaccines," <i>Develop. Biol. Standard</i> , 65:131-136 (1986)	
		Relyveld, et al., "Calcium Phosphate Adjuvanted Allergens, <i>Ann. Allergy</i> , 54(6):11-19 (1985)	
		Robinson et al., "Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA," <i>Vaccine</i> 11(9): 957-960 (1993).	
		Rolland, "New Vaccines for Allergic Rhinitis," Department of Pathology and Immunology, Monash University Medical School, Alfred Hospital, Melbourne, Australia, 2 pages (undated)	
		Rowland, et al., "The stability of liposome's in vitro to pH, bile salts and pancreatic lipase," <i>Biochem. Biophys. Acta.</i> , 620(3):400-9 (1980)	
		Santinho, et al., Influence of formulation on the physiochemical properties of casein microparticles, 186(2) <i>INTL. JOURNAL OF PHARMACEUTICS</i> , 191-98 (1999)	
		Sato et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," <i>Science</i> 273: 352-354 (1996).	
		Schafer et al., "Induction of a cellular immune response to a foreign antigen by a recombinant <i>Listeria monocytogenes</i> vaccine," <i>J. Immunol.</i> , 149(1):53-59 (1992).	
		Service, "Drug Delivery Takes a Deep Breath," <i>Science</i> , vol. 277, no.5330 (1997).	
		Stover et al., "New use of BCG for recombinant vaccines," <i>Nature</i> 351: 456-460 (1991).	
Examiner:		Date Considered:	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Form PTO-1449	Docket No.:	37070/293555	Application No.
	Applicant:	10/824,097	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Bell et al.	
	Filing Date: April 13, 2004	Group Art Unit 1654
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Takahashi et al., "Induction of CD8 cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs," <i>Nature</i> , 344: 873-875 (1990).
		Tang et al., "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> , 356: 152-154 (1992).
		Taylor and Askonas, "Influenza nucleoprotein-specific cytotoxic T-cell clones are protective <i>in vivo</i> ," <i>Immunol.</i> , 58(1): 417-420 (1986).
		Townsend, "Antigen recognition by class I-restricted T lymphocytes," <i>Annu. Rev. Immunol.</i> , 7: 601-624 (1989).
		Townsend et al., "The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes Can Be Defined with Short Synthetic Peptides," <i>Cell</i> 44: 959-968 (1986).
		Tozaki, et al., "Chitosan Capsules for Colon-Specific Drug Delivery: Improvement of Insulin Absorption from the Rat Colon," <i>J. Pharm. Sci.</i> , 86(9):1016-1021 (1997)
		Tragl, et al., "Oral administration of insulin by means of liposome's in animal experiments" (author's trans), <i>Wine Klin Wochenschr</i> , 91(13):448-51 (1979)
		Ulmer, J. B. et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," <i>Science</i> , 259: 1745-1749 (1993).
		Wang et al., "Gene inoculation generates immune responses against human immunodeficiency virus type I," <i>P.N.A.S. USA</i> 90: 4156-4160 (May, 1993).
		Wang, et al., "Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate," <i>Vaccine</i> , 18: 1227-1235 (2000).
		Weiner et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>PNAS (USA)</i> 94(19): 10833-10837 (1997).
		Willmott, et al., "Biodegradation rate of embolized protein microspheres in lung, liver and kidney of rats," <i>J. Pharm. Pharmacol.</i> , 41(7):433-438 (1989). (abstract)
		Willmott, et al., Doxorubicin-loaded casein microspheres: protein nature of drug incorporation, 44(6) <i>J. PHARM. PHARACOL</i> , 472-75 (1992)
		Wolff et al., "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle," <i>Human Mol. Genet.</i> 1(6): 363-369 (1992).
		Wolff et al., "Direct Gene Transfer into Mouse Muscle <i>in Vivo</i> ," <i>Science</i> 247: 1465-1468 (1990).
		Yablonski, et al., "A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics," <i>Exp. Eye Res.</i> , 27:135-142 (1978)
		Yap and Ada, "Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus," <i>Nature</i> , 273: 238-239 (1978).
		Yewdell et al., "Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. (USA)</i> 82: 1785-1789 (1985).
		Zhu et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," <i>Science</i> 261: 209-211 (1993).
Examiner:		Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket No.: 37070/293555	Application No. 10/824,097
	Applicant: Bell et al.	
	Filing Date: April 13, 2004	Group Art Unit 1654
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
		http://vaxa.com/html/669.cfm (09/10/00)
		Academic Press Dictionary of Science and Technology, http://www.harcourt.com/dictionary/def/2/2/3/1/2231200.html , No. 2000 (11/03/00)
		Food and Drug Administration Center for Drugs and Biologics Summar Minutes Allergenic Products Advisory Committee Meeting 5, 13 pages, June 25-26, 1987
Examiner:		Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		